APRIL 07, 2022

Biophytis announces its audited financial results for the year ended nDecember 31, 2021, and provides updates on key operational achievements nas well as perspectives for 2022

n
  • Success of Nasdaq IPO in February 2021
    • n
  • u20ac23.9M of available cash on December 31 2021 and new financing instruments for a total of u20ac42M allowing financial visibility beyond mid 2023
    • n
  • Strong growth of operational expenses to u20ac26.8M, mainly reflecting clinical program advancement in COVID-19 (COVA) and in sarcopenia (SARA)
    • n
  • Significant milestones reached for COVA and SARA allowing to prepare for future development of the programs
    • n
Download the Press Release
Fullscreen Mode

Other Press Releases

Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half…

Read more

BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia Creation of a joint venture in Hong…

Read more

Biophytis to Participate in Four Key Events in Q4 2025 Biophytis announces its participation in four major international events that reflect the complementarity of its development strategy: CF&B Midcap Events…

Read more

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners Biophytis announces major progress in preparing its OBA Phase 2 trial…

Read more

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 3 SARA trial…

Read more

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity Biophytis announces that the European Medicines Agency (EMA) has issued a favorable outcome on Part I of…

Read more